

Lung Metabolism

Proteolysis and Antiproteolysis
Biochemical Pharmacology
Handling of Bioactive Substances

Edited by
Alain F. Junod
Rodolphe de Haller

Lung Metabolism

*Proteolysis and Antiproteolysis
Biochemical Pharmacology
Handling of Bioactive Substances*

Edited by
Alain F. Junod

*Division de Pneumologie
Département de Médecine
Hôpital Cantonal
Genève
Switzerland*

Rodolphe de Haller

*Basler Höhenlinik
Davos
Switzerland*



Academic Press, Inc.

New York San Francisco London 1975
A Subsidiary of Harcourt Brace Jovanovich, Publishers

COPYRIGHT © 1975, BY ACADEMIC PRESS, INC.

ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.

111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by

ACADEMIC PRESS, INC. (LONDON) LTD.

24/28 Oval Road, London NW1

Library of Congress Cataloging in Publication Data

Davos Symposium, 5th, 1974.

Lung metabolism.

Bibliography: p.

Includes indexes.

1. Lungs--Congresses. 2. Lungs--Diseases--
Congresses. I. Junod, Alain F. II. Haller,
Rodolophe de. III. Title. [DNLM: 1. Lung--Metabolism
--Congresses. WF600 L965 1974]
QP121.D33 1974 612'.2 75-13070
ISBN 0-12-392250-X

PRINTED IN THE UNITED STATES OF AMERICA

List of Contributors

Numbers in parentheses indicate the pages on which the authors' contributions begin.

E. Änggård, (301) Department of Pharmacology, Karolinska Institutet, 104 01 Stockholm 60, Sweden

Y.S. Bakhle, (293) (347) Department of Pharmacology, Institute of Basic Medical Sciences, Royal College of Surgeons of England, 35/43 Lincoln's Inn Fields, London WC2A 3PN, Great Britain

Elizabeth S.N. Bannerman, (57) Veterinär-bakteriologisches Institut der Universität Bern, CH-3001 Bern, Switzerland

J. Bignon, (425) Laboratoire d'Histologie et Cytologie Pulmonaire, Clinique Pneumo-Phthisiologique, Hôpital Laennec, 42 rue de Sèvres, F-75007 Paris, France

B. Burns, (159) Department of Environmental Medicine, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, Maryland 21205

U.H. Cegla, (123) ZIMK, Sektion Pulmonologie, Universitätsklinik, Steinhövelstrasse 9, D-79 Ulm, W. Germany

Y.N. Cha, (159) Department of Pathobiology, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, Maryland 21205

G.M. Cohen, (185) Department of Biochemistry, University of Surrey, Guildford GU2 5XH, Surrey, Great Britain

M.E. Conolly, (233) (275) Department of Clinical Pharmacology, Royal Postgraduate Medical School, Hammersmith Hospital, Ducane Road, London W12 0HS, Great Britain

S. Cook, (481) Department of Surgery, Cardiothoracic Institute, 2 Beaumont Street, London W1N 2DX, Great Britain

D.S. Davies, (201) (275) Department of Clinical Pharmacology, Royal Postgraduate Medical School, Hammersmith Hospital, Ducane Road, London W12 0HS Great Britain

LIST OF CONTRIBUTORS

- D. Depierre**, (337) Laboratoire Central, Hôpital Cantonal, CH-1211 Genève, Switzerland
- F. Dray**, (365) Hôpital Laennec, 42 rue de Sèvres, F-75007 Paris, France
- F. Duckert**, (251) Gerinnungslaboratorien, Departement für Innere Medizin, Kantonsspital, CH-4004 Basel, Switzerland
- P. Duroux**, (365) Hôpital Laennec, 42 rue de Sèvres, F-75007 Paris, France
- P. Even**, (365) Hôpital Laennec, 42 rue de Sèvres, F-75007 Paris, France
- L. Favre**, (435) Division d'Endocrinologie, Département de Médecine Interne, Hôpital Cantonal, CH-1211 Genève, Switzerland
- B. Friedli**, (445) Clinique de Pédiatrie, Hôpital Cantonal, CH-1211 Genève, Switzerland
- J.K. Greenacre**, (233) Department of Clinical Pharmacology, Royal Postgraduate Medical School, Hammersmith Hospital, Ducane Road, London W12 OHS, Great Britain
- P.J. Grob**, Immunologisches Labor, Departement für Innere Medizin, Kantonsspital, CH-8006 Zürich, Switzerland
- G.H. Gurtner**, (159) Department of Environmental Medicine, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, Maryland 21205
- R. de Haller**, (57) Basler Höhenklinik, CH-7260 Davos-Dorf, Switzerland
- D. Heath**, (263) Department of Pathology, University of Liverpool, Liverpool, Great Britain
- N. Heimbürger**, (3) Behringwerke AG, D-3550 Marburg/Lahn, W. Germany
- K. Hochstrasser**, (101) Universitäts-HNO-Klinik, D-8000 München 2, W. Germany
- A.F. Junod**, (219) (387) Division de Pneumologie, Département de Médecine, Hôpital Cantonal, CH-1211 Genève, Switzerland
- D. Kaiser**, (107) Medizinische Universitätskinderklinik, Inselspital, CH-3010 Bern, Switzerland

LIST OF CONTRIBUTORS

- P. Kehrli**, (107) Medizinische Universitätskinderklinik, Inselspital, CH-3010 Bern, Switzerland
- P. Kimbel**, (25) Albert Einstein Medical Center, Northern Division, Pulmonary Disease Section, Philadelphia, Pennsylvania 19141
- F. Kueppers**, (67) Thoracic Diseases and Internal Medicine, Mayo Clinic, Rochester, Minnesota 55901
- J. Lieberman**, (83) Department of Respiratory Diseases, City of Hope Medical Center, Duarte, California 91010
- A.F. Muller**, (435) Division d'Endocrinologie, Département de Médecine Interne, Hôpital Cantonal, CH-1211 Genève, Switzerland
- J. Nicolet**, (57) Veterinär-bakteriologisches Institut der Universität Bern, CH-3001 Bern, Switzerland
- D.J. Parker**, (459) (481) Department of Surgery, Cardiothoracic Institute, 2 Beaumont Street, London W1N 2DX, Great Britain
- H. Peavy**, (159) Department of Environmental Medicine, Johns Hopkins University, 615 N. Wolfe Street, Baltimore, Maryland 21205
- Priscilla J. Piper**, (315) (325) Department of Pharmacology, Institute of Basic Medical Sciences, Royal College of Surgeons, 35/43 Lincoln's Inn Fields, London WC2A 3PN, Great Britain
- R. Reichert**, (101) Universitäts-HNO-Klinik, D-8000 München 2, W. Germany
- H. Remmer**, (133) Institut für Toxikologie, Universität Tübingen, D-7400 Tübingen, W. Germany
- O.M. Rennert**, (107) Medizinische Universitätskinderklinik, Inselspital, CH-3010 Bern, Switzerland
- M. Roth**, (337) Laboratoire Central, Hôpital Cantonal, CH-1211 Genève, Switzerland
- F. Ruff**, (365) Hôpital Laennec, 42 rue de Sèvres, F-57007 Paris, France
- J.W. Ryan**, (399) Papanicolaou Cancer Research Institute, P.O. Box 6188, Miami, Florida 33123

LIST OF CONTRIBUTORS

Una S. Ryan, (399) Papanicolaou Cancer Research Institute, P.O. Box 6188, Miami, Florida 33123

MC. Santais, (365) Hôpital Laennec, 42 rue de Sèvres, F-75007 Paris, France

K. Schorn, (101) Universitäts-HNO-Klinik, D-800 München 2, W. Germany

D. Sidiropoulos, (107) Medizinische Universitätskinderklinik, Inselspital, CH-3010 Bern, Switzerland

H. Sors, (365) Hôpital Laennec, 42 rue de Sèvres, F-75007 Paris, France

Margaret Turner-Warwick, (481) Department of Medicine, Cardiothoracic Institute, Fulham Road, London SW3 6HP, Great Britain

M.B. Vallotton, (435) Division d'Endocrinologie, Département de Médecine Interne, Hôpital Cantonal, CH-1211 Genève, Switzerland

G. Weinbaum, (25) Albert Einstein Medical Center, Northern Division, Pulmonary Disease Section, Philadelphia, Pennsylvania 19141

H. Zuber, (43) Institut für Molekularbiologie und Biophysik, Eidg. Technische Hochschule, Hönggerberg, CH-8049 Zürich, Switzerland

Preface

The long held traditional view that the lung is solely and passively involved in gas exchanges has been profoundly altered by contemporary research, which attests to its capacity to perform various metabolic tasks. This new knowledge had accumulated gradually, and had neither been systematized nor assessed. Therefore, it was decided to organize the Fifth Davos Symposium around these recent researches on the physiological and pathological nonventilatory functions of the lung, with the object of organizing this information and reviewing and evaluating the progress achieved. Accordingly, 28 experts involved in a number of relevant specialties gathered in Davos, Switzerland, October 7-9, 1974, to discuss their experimental and clinical findings.

The early phases of the conference were devoted to considering the response of the lung involved in preserving its integrity against enzymes, both exogenous (bacterial and mycotic) and endogenous, such as those coming from leucocytes or lung tissue itself. The balance between release of proteolytic enzymes and production of antiproteolytic substances in the lung may well be an important factor in the genesis of obstructive pulmonary disease. A better understanding of the mechanisms involved is also likely to play a major role in developing meaningful therapeutic modalities.

In succeeding segments of the conference specialists in various fields emphasized the capability of the lung to metabolize exogenous substances arriving by inhalation and by digestive or parenteral absorption. Much time was devoted to discussion of the role of the lung in homeostatic processes of the whole organism, such as coagulation, production and destruction of hormones and other biologically active substances. These metabolic functions of the lung are important per se and possibly as an alternative fail-safe system, should other organs, such as liver or kidney—more regularly involved in these processes—for any reason be rendered insufficient. Experimental researches on animals all too frequently disclose major species variations; special emphasis was therefore placed on the unique potential of cardiopulmonary bypass in man as a major investigative tool completely obviating these laboratory animal uncertainties. An understanding of the range and diversity of metabolic functions of lung is certainly valuable in terms of clinical management and moreover offers distinctive approaches for therapeutic explorations.

This volume consists of the formal presentations which in many instances also review the key literature, and an edited version of the individual and general discussions. The photocopy process for reproduction was utilized as the most efficient means of facilitating early publication; consequently, the con-

tributors had no further opportunity to modify their remarks. We thank Professor M. Landy for editorial guidance, particularly in coping with the discussion transcripts. We acknowledge with thanks the expertise and devotion of our secretaries, Mrs. R. Kindschi and A. Meylan, in the complex and exacting task of preparing the camera-ready typescript. Financial support for this symposium was kindly provided by the Swiss National Science Foundation, Grant No. 3.3120.74.

These proceedings bring to clinicians and basic scientists a wealth of information and commentary on all too little known aspects of lung functions. It is our hope that this volume will provide an organized source of information on these distinctive attributes of lung and help point the way for future work by focusing on continuing major problems and issues.

A.F. Junod

R. de Haller

Contents

<i>List of Contributors</i>	ix
<i>Preface</i>	xiii

Section I PROTEOLYSIS AND ANTIPROTEOLYSIS IN THE LUNG

Chairman: P.J. Grob

Properties and Role of Antiproteases <i>N. Heimburger</i>	3
Role of Leucoproteases in the Genesis of Emphysema <i>P. Kimbel and G. Weinbaum</i>	25
Bacterial Proteolytic Enzymes <i>H. Zuber</i>	43
Mycotic Proteolytic Enzymes <i>J. Nicolet, Elizabeth S.N. Bannerman, and R. de Haller</i>	57
Genetic Considerations on Alpha ₁ -Antitrypsin Deficiency <i>F. Kueppers</i>	67
Clinical Spectrum of Alpha ₁ -Antitrypsin Deficiency <i>J. Lieberman</i>	83
The Antiproteolytic System of the Upper Respiratory Tract <i>K. Hochstrasser, R. Reichert, and K. Schorn</i>	101
Studies of Alpha ₁ -Antitrypsin in Amniotic Fluid, Meconium and Cord Serum of a Homozygote Newborn Infant <i>D. Kaiser, D. Sidiropoulos, P. Kehrli, and O.M. Rennert</i>	107
Influence of Intravenous Injection of D-Penicillamine and Trasylol® on the Serum Levels of Alpha ₁ -Antitrypsin in Human Subjects <i>U.H. Cegla</i>	123

Section II BIOCHEMICAL PHARMACOLOGY OF THE LUNG

Chairman: H. Remmer

Pulmonary Drug-Metabolizing Enzymes <i>H. Remmer</i>	133
---	-----

CONTENTS

A Specific Carrier for Oxygen and Carbon Monoxide in the Lung <i>B. Burns, G.H. Gurtner, H. Peavy, and Y.N. Cha</i>	159
Pulmonary Metabolism of Inhaled Substances and Possible Relationship with Carcinogenicity and Toxicity <i>G.M. Cohen</i>	185
Metabolism of Drugs Administered by Aerosol <i>D.S. Davies</i>	201
Mechanisms of Drug Accumulation in the Lung <i>A.F. Junod</i>	219
Hormone Receptors in the Lung <i>M.E. Conolly and J.K. Greenacre</i>	233
Lung and Coagulation <i>F. Duckert</i>	251
Drug-Induced Pulmonary Changes <i>D. Heath</i>	263
Paraquat Poisoning—Possible Therapeutic Approach <i>D.S. Davies and M.E. Conolly</i>	275
General Discussion	279

Section III HANDLING OF BIOACTIVE SUBSTANCES BY THE LUNG

Chairman: Y.S. Bakhle

The Pharmacokinetic Function of Lung <i>Y.S. Bakhle</i>	293
Biosynthesis and Metabolism of Prostaglandins in the Lung <i>E. Ånggård</i>	301
Conditions of Release of Prostaglandins from the Lung <i>Priscilla J. Piper</i>	315
Importance and Nature of the Mechanism of Inactivation of Prostaglandins in the Lung <i>Priscilla J. Piper</i>	325
Dipeptidyl Carboxypeptidase in Lung and Blood Plasma <i>M. Roth and D. Depierre</i>	337
Bradykininase and Converting Enzyme in Lung <i>Y.S. Bakhle</i>	347

CONTENTS

Measurement of Prostaglandins E 1, E 2, and F α , Histamine and Serotonin, Upstream and Downstream the Lung during Pulmonary Vasopressor Response to Hypoxia in Man. Effects of Prostaglandin Synthesis Inhibitors. <i>P. Even, F. Dray, F. Ruff, P. Duroux, MC. Santais, and H. Sors</i>	365
Mechanism of Uptake of Biogenic Amines in the Pulmonary Circulation <i>A.F. Junod</i>	387
Metabolic Activities of Plasma Membrane and Caveolae of Pulmonary Endothelial Cells, with a Note on Pulmonary Prostaglandin Synthetase <i>J.W. Ryan and Una S. Ryan</i>	399
Several Plasma Proteins Demonstrated in Lung Tissue by Immunoelectron Microscopy using the Peroxidase Coupling Technique <i>J. Bignon</i>	425
Cardiopulmonary Bypass and Conversion of Angiotensin I in Man <i>L. Favre, M.B. Vallotton, and A.F. Muller</i>	435
Clinical Aspects of Hydrolysis of Vasoactive Peptides in the Pulmonary Circulation <i>B. Friedli</i>	445
Some Changes in the Lungs Associated with Cardiopulmonary Bypass <i>D.J. Parker</i>	459
Serum Complement Studies during and following Cardiopulmonary Bypass <i>D.J. Parker, S. Cook, and Margaret Turner-Warwick</i>	481
General Discussion	489
Concluding Remarks <i>A.F. Junod</i>	493
<i>Author Index</i>	495
<i>Subject Index</i>	497

Section I

Proteolysis and Antiproteolysis in the Lung

PROPERTIES AND ROLE OF ANTIPROTEASES

N. Heimbürger

Proteinase inhibitors (PI's) are a group of peptides and proteins characterized by their ability to block the catalytic site of proteolytic enzymes; they have been detected in all living organisms, in plants as well as in bacteria and animals. They have been found in varying concentrations in different tissues of mammals. High amounts of PI's are localized in secretory glands and in plasma. From the beginning of this century PI's became of increasing interest in regard to their wide distribution and universal function. It is now well established that PI's control proteinases involved in various biological processes: Release of proteo-hormones (insulin), activation of zymogens, digestion of food, phagocytosis, immunodefense, inflammation, fertilization, blood coagulation, fibrinolysis and growth both normal and malignant.

The earliest observations concerning the antiproteolytic activity of serum were published at the end of last century (6, 13, 16), however it took another fifty years until six PI's of human plasma were isolated and characterized chemically as well as biologically (references in 20, 21).

Identification of six inhibitors in human plasma

Human plasma can be shown to contain at least six PI's when starch gel electrophoresis and fibrin containing agar plates are combined according to the sandwich principle (39). This technique is demonstrated in Figure 1. To prove the presence of PI's, plasma is separated electrophoretically in starch gel. The gel is then cut into two discs; the upper one is stained with amido black and the lower one is used to cover agar plates containing heat-inactivated fibrin. As soon as the proteins have entered the fibrin-agar film, troughs parallel to the migration direction are cut and filled with enzyme solutions. The substrate plates are then incubated at 37° C for about 20 hours. During this time, the proteases enter the gel. Diffusion is evidenced by lysis of the fibrin. Fibrin remains intact only in the electrophoretic positions of the inhibitors. By this technique, plasma can be shown to contain inhibitors against elastase, plasmin, trypsin, chymotrypsin; five of a total of six proved to be polyvalent. The




Fig. 1. Identification of six proteinase inhibitors in human plasma. Starch gel electrophoresis was used in combination with fibrin agar plates according to the sandwich technique. A. electrophoretic pattern of plasma stained with amido-black; B. fibrin plates after being covered with and lysed by elastase; C. plasmin; D. trypsin, and E. chymotrypsin.

(Heimbürger et al., 1971) (Reproduced with permission of the publisher)

PI's have been designated according to their electrophoretic mobility and with respect to their most important physiological function known at the time of isolation.

Table 1 lists the names of the inhibitors together with their useful abbreviations and the normal concentration ranges in which they are found in human plasma. The inhibitors below the line (7-9) have not yet been isolated in pure and active form, however they have been traced by their function. Consequently it might be suggested that, in addition to α_2 -macroglobulin (α_2 M), there is a further inhibitor of thiol proteinases in plasma. There is also evidence for further inhibitors of clotting factors. It concerns the inhibition of F XIa by a protein not characterized up to now.

Figure 2 shows the main plasmatic inhibitors characterized by means of polyacrylamide gel electrophoresis. As might be expected α_1 -antitrypsin (α_1 A) and α_1 -antichymotrypsin (α_1 X) migrate in front of the plasma proteins, α_2 -macroglobulin (α_2 M) and C1-inactivator (C1 INA) remain near the starting point and the inter- α -trypsin inhibitor (I α I) and anti-thrombin III (AT III) are found in between.

Figure 3 shows the plasmatic PI's characterized by means of immunoelectrophoresis and specific antisera. To indicate the electrophoretic positions of the PI's, human serum was separated on a plate containing heat-denatured fibrin which was developed thereafter by an antiserum to total human serum and trypsin as well (plate A in Fig. 3). It is evident that all plasmatic PI's migrate together with the α_1 - and α_2 -globulins. The plates B to G show electrophoretic patterns of human serum after developing with specific antisera to the six inhibitors. With the double diffusion technique of Ouchterlony we were able to demonstrate that the six PI's are individual proteins not related to each other.

All PI's are glycoproteins; the most relevant data are listed in Table 2 (20) including mean concentrations found in serum, molecular weight, peptide and carbohydrate content. As for concentration, α_1 A and α_2 M are predominant, while the other inhibitors are only present in traces in human serum. The concentration of all plasma inhibitors amounts up to about 700 mg/100 ml, that means 10% of the plasma proteins are carriers of inhibitor functions. The molecular weights vary from 54.000 for α_1 A to 725.000 for α_2 M (25). Even the carbohydrate content differs from one inhibitor to the other: α_1 A and C1 INA are especially rich, containing 25% and 35%.